Node negative breast cancer.
نویسندگان
چکیده
منابع مشابه
DNA histogram analysis for node-negative breast cancer.
The combination of DNA ploidy and S-phase is one of the strongest general prognostic indicators for node-negative breast cancer (1). The costs associated with this prognostic power are relatively minimal; laboratory total processing time is usually less than 10 min and reagents are relatively inexpensive. The test can be standardized world-wide as long as strict guidelines are followed, and the...
متن کاملAdjuvant docetaxel for high-risk, node-negative breast cancer.
BACKGROUND A regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) is superior to a regimen of fluorouracil, doxorubicin, and cyclophosphamide (FAC) when used as adjuvant therapy in women with node-positive breast cancer. The value of taxanes in the treatment of node-negative disease has not been determined. METHODS We randomly assigned 1060 women with axillary-node-negative breast ca...
متن کاملCoordinates in the universe of node-negative breast cancer revisited.
We present a global picture of the natural history of node-negative breast cancer in which two of three important biological processes have outstanding prognostic consequences. We propose that the transition from slow to fast proliferation of the tumor leads to the most dramatic aggravation of prognosis. Second, immune cell infiltration is of major importance to prevent disease progression in f...
متن کامل[Prognostic factors in lymph node negative breast cancer].
.................................................................................6 LIST OF PUBLICATIONS...............................................................13 ABBREVIATIONS.........................................................................14
متن کاملResponse to Paclitaxel in Node-positive Triple Negative Breast Cancer
Purpose: Triple negative breast cancer (TNBC) has had poor prognosis compared with the luminal subtype. And there has been no benefit from doxorubicin. However, the addition of paclitaxel is known to improve both disease-free survival (DFS) and overall survival (OS). The aim of our study was to assess the effect of the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1990
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.300.6721.346